18417-89-5

18417-89-5 structure

Name: Sangivamycin
Chemical Name: sangivamycin
CAS Number: 18417-89-5
Molecular Formula: C₁₂H₁₅N₅O₅
Molecular Weight: 309.28
Catalog: Signaling Pathways Cell Cycle/DNA Damage Nucleoside Antimetabolite/Analog
Create Date: 2018-02-25 08:00:00
Modify Date: 2025-08-25 23:56:32
Sangivamycin (NSC 65346), a nucleoside analog, is a potent inhibitor of protein kinase C (PKC) with an Ki of 10 μM. Sangivamycin has potent antiproliferative activity against a variety of human cancers[1][2].

Name	sangivamycin
Synonyms	7-Carboxamido-7-deazaadenosine 7-DEAZA-7-CARBAMOYLADENOSINE 7-DEAZAADENOSINE-7-CARBOXAMIDE SANGIVAMYCIN

Description	Sangivamycin (NSC 65346), a nucleoside analog, is a potent inhibitor of protein kinase C (PKC) with an Ki of 10 μM. Sangivamycin has potent antiproliferative activity against a variety of human cancers[1][2].
Related Catalog	Signaling Pathways >> Epigenetics >> PKC Research Areas >> Cancer Signaling Pathways >> Cell Cycle/DNA Damage >> Nucleoside Antimetabolite/Analog Signaling Pathways >> TGF-beta/Smad >> PKC
In Vitro	Sangivamycin has differential antitumor effects in drug-sensitive MCF7/wild type (WT) cells, causing growth arrest, and in multidrug-resistant MCF7/adriamycin-resistant (ADR) human breast carcinoma cells, causing massive apoptotic cell death[2]. Sangivamycin (0.3 μM; 0-72 hours), shows almost maximal cytocidal (for MCF7/ADR) or cytostatic (for MCF7/WT) effects[2]. Sangivamycin activates caspases in MCF7/ADR cells. Upon exposure of MCF7/ADR cells to Sangivamycin (0.3 μM;), a vast amount of cleavage of lamin A to a 28-kDa fragment is detected within 48 hours[2].
References	[1]. Loomis CR, Bell RM. Sangivamycin, a nucleoside analogue, is a potent inhibitor of protein kinase C. J Biol Chem. 1988;263(4):1682-1692. [2]. Lee SA, et al. The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation. J Biol Chem. 2007;282(20):15271-15283.

CHEMICAL NAME :: 7H-Pyrrolo(2,3-d)pyrimidine-5-carboxamide, 4-amino-7-beta-D-ribofuranosyl-

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut Sts., Philadelphia, PA 19106) V.1- 1941- Volume(issue)/page/year: 41,1784,1981

Symbol	GHS06
Signal Word	Danger
Hazard Statements	H300-H310-H330
Precautionary Statements	P260-P264-P280-P284-P302 + P350-P310
Personal Protective Equipment	Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges
Hazard Codes	T+
Risk Phrases	26/27/28
RIDADR	UN 2811 6.1/PG 2
RTECS	UY9355000

Precursor 0
DownStream 1
65562-56-3